Market Access Nine for 2024, Pt 1: From fragility to resilience This year was a year of significant new beginnings for pharma and healthcare, yet, it was still impacted by the long-term fallouts of the pandemic.
News CAR-Ts to take centre stage at ASH haematology congress Haematology is one of the most exciting areas in drug development today, with waves of new treatments emerging for hard-to-treat diseases.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.